Group 1 - The chairman and CEO of the company, Dr. Tong Youzhi, increased his stake in the company by purchasing 200,000 shares for HKD 259,000 at an average price of HKD 1.295 per share, representing approximately 0.0447% of the total issued share capital as of the announcement date [1] - Dr. Tong exercised rights to 1.25 million restricted stock units, corresponding to 1.25 million ordinary shares, which vested on March 31, 2025 [1] - Following this acquisition, Dr. Tong holds a total of 49.2003 million shares, representing about 10.99% of the total issued share capital as of the announcement date [1] Group 2 - The increase in shareholding demonstrates Dr. Tong's strong confidence in the company's commercialization prospects and growth potential, as well as recognition of its long-term investment value [2] - The company plans to continue focusing on the dermatology field, enhancing existing cosmetic products, broadening product coverage, and accelerating the launch of new cosmetic products to enrich its product matrix [2] - The company is actively exploring the market potential for effective raw materials, specifically KT-939 and KX-826, and is seeking collaboration opportunities with cosmetic brand owners to expand its raw material business and cultivate new profit growth points [2]
开拓药业-B(09939)获行政总裁童友之增持145万股